OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M

ORTHOPEDIATRICS CORP

2025-Q1 EPS reported -$0.46 revenue$52,411,000

Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).
Net loss $10.7M ($0.46 per share) vs. $7.8M ($0.34) in Q1 2024; adjusted EBITDA loss improved to ($0.4M) from ($1.1M).
FY2025 revenue guidance raised to $236M-$242M (15-18% growth); adjusted EBITDA guidance reiterated at $15-17M.
Scoliosis revenue grew 34% to $13.7M; launched VerteGlide system for Early Onset Scoliosis.
Cash, equivalents and restricted cash $60.8M at quarter end vs. $70.8M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.